The U.S. Food and Drug Administration has approved Pfizer Inc.'s (PFE) PREVNAR 20 or Pneumococcal 20-valent Conjugate Vaccine for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae or pneumococcus serotypes in the vaccine in adults ages 18 years and older.
The Russian Health Ministry has issued a permit to conduct the post-registration clinical trials of the CoviVac shot against the coronavirus infection with the...
Pharmaceutical holding Nacimbio of Rostec State Corporation will create new production facilities at NPO Microgen subsidiaries in Ufa, Perm and Tomsk. Biotechnology products, including...
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Sanofi, one of the leading global pharmaceutical companies, agree to cooperate for joint...